The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea

[1] Chey WD(2015)Irritable bowel syndrome: A clinical review Journal of the American Medical Association 313 949-958

[2] Kurlander J(2016)Bowel disorders Gastroenterology 150 1393-1407

[3] Eswaran S(2014)The epidemiology of irritable bowel syndrome Clinical Epidemiology 6 71-80

[4] Lacy BE(2012)Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis Clinical Gastroenterology and Hepatology 10 712-721

[5] Mearin F(2014)Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern Neurogastroenterology and Motility 26 36-45

[6] Chang L(2007)Guidelines on the irritable bowel syndrome: Mechanisms and practical management Gut 56 1770-1798

[7] Chey WD(2017)Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea Health and Quality of Life Outcomes 15 35-8109

[8] Lembo AJ(2015)Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation World Journal of Gastroenterology 21 8103-1125

[9] Simren M(2012)Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/µ opioid receptor antagonist British Journal of Pharmacology 167 1111-253

[10] Spiller R(2016)Eluxadoline for irritable bowel syndrome with diarrhea New England Journal of Medicine 374 242-1328

[1] Chey WD(2015)Irritable bowel syndrome: A clinical review Journal of the American Medical Association 313 949-958

[2] Kurlander J(2016)Bowel disorders Gastroenterology 150 1393-1407

[3] Eswaran S(2014)The epidemiology of irritable bowel syndrome Clinical Epidemiology 6 71-80

[4] Lacy BE(2012)Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis Clinical Gastroenterology and Hepatology 10 712-721

[5] Mearin F(2014)Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern Neurogastroenterology and Motility 26 36-45

[6] Chang L(2007)Guidelines on the irritable bowel syndrome: Mechanisms and practical management Gut 56 1770-1798

[7] Chey WD(2017)Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea Health and Quality of Life Outcomes 15 35-8109

[8] Lembo AJ(2015)Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation World Journal of Gastroenterology 21 8103-1125

[9] Simren M(2012)Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/µ opioid receptor antagonist British Journal of Pharmacology 167 1111-253

[10] Spiller R(2016)Eluxadoline for irritable bowel syndrome with diarrhea New England Journal of Medicine 374 242-1328